RU2011110504A - Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды - Google Patents
Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды Download PDFInfo
- Publication number
- RU2011110504A RU2011110504A RU2011110504/10A RU2011110504A RU2011110504A RU 2011110504 A RU2011110504 A RU 2011110504A RU 2011110504/10 A RU2011110504/10 A RU 2011110504/10A RU 2011110504 A RU2011110504 A RU 2011110504A RU 2011110504 A RU2011110504 A RU 2011110504A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- antigen
- group
- cancer
- peptide according
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 10
- 229960005486 vaccine Drugs 0.000 title claims 2
- 101001054725 Homo sapiens Inhibin beta B chain Proteins 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract 10
- 239000000427 antigen Substances 0.000 claims abstract 10
- 102000036639 antigens Human genes 0.000 claims abstract 10
- 108091007433 antigens Proteins 0.000 claims abstract 10
- 201000011510 cancer Diseases 0.000 claims abstract 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract 9
- 102000040430 polynucleotide Human genes 0.000 claims abstract 9
- 108091033319 polynucleotide Proteins 0.000 claims abstract 9
- 239000002157 polynucleotide Substances 0.000 claims abstract 9
- 210000001808 exosome Anatomy 0.000 claims abstract 7
- 150000001413 amino acids Chemical group 0.000 claims abstract 5
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 229930182817 methionine Natural products 0.000 claims abstract 2
- 230000002980 postoperative effect Effects 0.000 claims abstract 2
- 239000004474 valine Substances 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 201000010174 renal carcinoma Diseases 0.000 claims 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8997308P | 2008-08-19 | 2008-08-19 | |
| US61/089,973 | 2008-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011110504A true RU2011110504A (ru) | 2012-09-27 |
Family
ID=41707002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011110504/10A RU2011110504A (ru) | 2008-08-19 | 2009-08-14 | Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20110280898A1 (enExample) |
| EP (1) | EP2326718A4 (enExample) |
| JP (1) | JP2012500001A (enExample) |
| KR (1) | KR20110063456A (enExample) |
| CN (1) | CN102186977A (enExample) |
| AU (1) | AU2009283762A1 (enExample) |
| CA (1) | CA2734515A1 (enExample) |
| IL (1) | IL211131A0 (enExample) |
| MX (1) | MX2011001880A (enExample) |
| RU (1) | RU2011110504A (enExample) |
| SG (1) | SG193214A1 (enExample) |
| TW (1) | TW201008574A (enExample) |
| WO (1) | WO2010021111A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2325306T3 (en) * | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide |
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| CN101432022A (zh) * | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| EP2004687A1 (en) * | 2006-02-28 | 2008-12-24 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-cdh3 antibodies |
| EP2468887A1 (en) * | 2006-12-13 | 2012-06-27 | Oncotherapy Science, Inc. | TTK as tumor marker and therapeutic target for lung cancer |
| EP2185732A1 (en) * | 2007-07-30 | 2010-05-19 | Oncotherapy Science, Inc. | Cancer associated gene ly6k |
| UA100127C2 (ru) * | 2007-08-20 | 2012-11-26 | Онкотерапи Саенс, Инк. | Пептид cdh3 и лекарственное средство, содержащее его |
| CA2729403A1 (en) | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| TWI543767B (zh) | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| MX2011004176A (es) | 2008-10-22 | 2011-09-21 | Oncotherapy Science Inc | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. |
| TWI539160B (zh) | 2008-12-05 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| CN102781964B (zh) | 2009-12-28 | 2015-11-25 | 肿瘤疗法科学股份有限公司 | 抗cdh3抗体及其用途 |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| TWI538685B (zh) * | 2010-04-02 | 2016-06-21 | 腫瘤療法 科學股份有限公司 | Ｅｃｔ２胜肽及含此胜肽之疫苗 |
| EP2795329A2 (en) * | 2011-12-23 | 2014-10-29 | Medical Research Council | Selective ligands for the angiotensin ii receptors |
| KR20140138900A (ko) * | 2012-03-09 | 2014-12-04 | 온코세라피 사이언스 가부시키가이샤 | 펩티드를 포함한 의약 조성물 |
| EP2872531A4 (en) * | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME |
| WO2014010231A1 (en) * | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
| SG11201504558TA (en) | 2012-12-11 | 2015-07-30 | Einstein Coll Med | Methods for high throughput receptor:ligand identification |
| TWI658049B (zh) * | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| US10576097B2 (en) * | 2014-08-04 | 2020-03-03 | Oncotherapy Science, Inc. | URLC10-derived peptide and vaccine containing same |
| AU2015313268B2 (en) | 2014-09-08 | 2018-12-20 | National Cancer Center | Cancer-cell-specific antibody, anticancer agent, and cancer testing method |
| WO2016090177A1 (en) | 2014-12-03 | 2016-06-09 | Verik Bio, Inc. | Identification, selection and use of high curative potential t cell epitopes |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| SG11201808552XA (en) | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| BR112019018307A2 (pt) * | 2017-03-03 | 2020-03-31 | Treos Bio Zrt | Plataforma para identificação de peptídeos imunogênicos baseada em população |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| EP3630131B1 (en) | 2017-06-02 | 2022-08-31 | Arizona Board of Regents on behalf of Arizona State University | A method to create personalized canine cancer vaccines |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN113329761A (zh) | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN120842365B (zh) * | 2025-07-25 | 2026-05-29 | 广州医科大学附属第一医院（广州呼吸中心） | 淋巴细胞抗原6复合物位点k的抗原表位肽及其应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3322314C2 (de) | 1983-06-21 | 1986-01-02 | Gebhard, Dietrich, 7502 Malsch | Schaltungsanordnung für ein Zugfahrzeug |
| US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| NZ217727A (en) | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
| IL103928A0 (en) | 1991-12-11 | 1993-04-04 | American Home Prod | Expression of specific immunogens using viral antigens |
| EP0756627A1 (en) | 1994-04-15 | 1997-02-05 | Amgen Inc. | Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases |
| AU6795898A (en) | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| EP1627886A1 (en) | 1997-10-07 | 2006-02-22 | Ono Pharmaceutical Co., Ltd. | Polypeptide, cDNA encoding the same, and use of them |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| US20070014787A1 (en) * | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
| CN1262562C (zh) | 1998-07-28 | 2006-07-05 | 株式会社绿多肽 | 来源于sart－1的hla－a2限制性肿瘤抗原肽 |
| DE60036477T2 (de) | 1999-08-04 | 2008-06-12 | Bacher, Adelbert, Prof. Dr.med. Dr.rer.nat. | Isoprenoid biosynthese |
| WO2001029221A2 (en) | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Proteins and polynucleotides encoding them |
| US6682902B2 (en) | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| JP2003524016A (ja) | 2000-02-23 | 2003-08-12 | エピミューン， インコーポレイテッド | Ｈｌａ結合ペプチドおよびそれらの用途 |
| AU2001238347A1 (en) | 2000-02-28 | 2001-09-12 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CN1469926A (zh) | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
| AU2001261007A1 (en) | 2000-03-29 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| WO2002008765A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Basal cell markers in breast cancer and uses thereof |
| US6830885B1 (en) | 2000-08-18 | 2004-12-14 | Phenogene Therapeutiques Inc. | Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature |
| US20090062512A1 (en) | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| US7033832B2 (en) | 2000-10-13 | 2006-04-25 | University Of Medicine And Dentistry Of New Jersey | Endothelial cell—cell cohesion |
| EP1474528A4 (en) | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| CN100400099C (zh) | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| CA2444691A1 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| MXPA03011979A (es) | 2001-06-18 | 2005-04-08 | Eos Biotechnology Inc | Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario. |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| WO2003080640A1 (en) | 2002-03-07 | 2003-10-02 | Ludwig Institute For Cancer Research | Lymphatic and blood endothelial cell genes |
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| CA2499709A1 (en) | 2002-06-19 | 2003-12-31 | Yoichi Furukawa | Method for diagnosis of colorectal tumors |
| JP2005532077A (ja) | 2002-07-10 | 2005-10-27 | オンコセラピー・サイエンス株式会社 | 腸型胃腫瘍の診断法 |
| FI116178B (fi) | 2002-08-22 | 2005-09-30 | Abb Oy | Vaihtosuuntaajan lähtökuristinsovitelma |
| WO2004035732A2 (en) | 2002-08-29 | 2004-04-29 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| JP4401295B2 (ja) | 2002-08-30 | 2010-01-20 | オンコセラピー・サイエンス株式会社 | 卵巣子宮内膜症の診断法 |
| US20050214836A1 (en) | 2002-08-30 | 2005-09-29 | Oncotherapy Science, Inc. | Method of diagnosing ovarian endometriosis |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200418988A (en) | 2002-09-30 | 2004-10-01 | Oncotherapy Science Inc | Method for diagnosing prostate cancer |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| CN1703522A (zh) | 2002-09-30 | 2005-11-30 | 肿瘤疗法科学股份有限公司 | 诊断睾丸精原细胞瘤的方法 |
| CN1703524B (zh) | 2002-09-30 | 2010-04-07 | 肿瘤疗法科学股份有限公司 | 与人胰腺癌相关的基因和多肽 |
| US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
| CA2500687A1 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20040224408A1 (en) | 2002-12-10 | 2004-11-11 | Jean-Philippe Girard | THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
| EP1572118A4 (en) | 2002-12-20 | 2010-07-14 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216 |
| TWI324608B (en) | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
| US7337154B2 (en) | 2003-05-19 | 2008-02-26 | Raytheon Company | Method for solving the binary minimization problem and a variant thereof |
| EP1651775A2 (en) | 2003-06-18 | 2006-05-03 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP4614952B2 (ja) | 2003-08-20 | 2011-01-19 | オンコセラピー・サイエンス株式会社 | 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２） |
| CN1898563B (zh) | 2003-09-24 | 2011-11-23 | 肿瘤疗法科学股份有限公司 | 诊断乳腺癌的方法 |
| JP2007536762A (ja) | 2003-12-08 | 2007-12-13 | シリコン イメージ，インコーポレイテッド | ツリー構造を有するシステムにおいて用いる統合型アドレス指定方式 |
| EP1730279A2 (en) | 2004-02-27 | 2006-12-13 | Oncotherapy Science, Inc. | Epha4 as therapeutic target of prc and pdaca |
| CN1977044A (zh) | 2004-03-24 | 2007-06-06 | 肿瘤疗法科学股份有限公司 | 治疗胰腺癌的组合物和方法 |
| EP2495324B1 (en) | 2004-04-09 | 2015-03-04 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| WO2006038208A2 (en) | 2004-07-12 | 2006-04-13 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment |
| WO2006055371A2 (en) | 2004-11-16 | 2006-05-26 | Alexion Pharmaceuticals, Inc. | Functional screening of antibody libraries |
| CN100381460C (zh) | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
| US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| CA2598889A1 (en) | 2005-02-24 | 2006-08-31 | Cemines, Inc. | Compositions and methods for classifying biological samples |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| DK2325306T3 (en) | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide |
| WO2006093337A1 (ja) | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | 癌の予防・治療剤 |
| CN100348614C (zh) | 2005-06-03 | 2007-11-14 | 北京大学 | 一种肝癌－睾丸特异性抗原蛋白质和抗原肽 |
| NZ591569A (en) | 2005-07-20 | 2012-10-26 | Agriculture Victoria Serv Pty | Modification of flavonoid biosynthesis in plants with transparent testa 2 |
| EP1907582B1 (en) | 2005-07-27 | 2012-01-04 | Oncotherapy Science, Inc. | Ect2 as a therapeutic target for esophageal cancer |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| EP1907580A2 (en) | 2005-07-28 | 2008-04-09 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| WO2007013480A2 (en) | 2005-07-29 | 2007-02-01 | Oncotherapy Science, Inc. | Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex |
| WO2007018047A1 (ja) | 2005-08-09 | 2007-02-15 | Kurume University | Hla-a24分子結合性扁平上皮癌抗原由来ペプチド |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| WO2007064743A2 (en) | 2005-11-30 | 2007-06-07 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| EP2004687A1 (en) | 2006-02-28 | 2008-12-24 | Oncotherapy Science, Inc. | Methods for damaging cells using effector functions of anti-cdh3 antibodies |
| CN101432022A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| EP2343551B1 (en) | 2006-04-10 | 2014-05-28 | Genentech, Inc. | Dishevelled PDZ modulators |
| EP2468887A1 (en) | 2006-12-13 | 2012-06-27 | Oncotherapy Science, Inc. | TTK as tumor marker and therapeutic target for lung cancer |
| WO2008102906A1 (en) | 2007-02-20 | 2008-08-28 | Oncotherapy Science, Inc. | Hspc-hrpc transition genes |
| TWI494319B (zh) | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| EP2185732A1 (en) | 2007-07-30 | 2010-05-19 | Oncotherapy Science, Inc. | Cancer associated gene ly6k |
| UA100127C2 (ru) | 2007-08-20 | 2012-11-26 | Онкотерапи Саенс, Инк. | Пептид cdh3 и лекарственное средство, содержащее его |
| EP2080812A1 (en) | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| TWI543767B (zh) | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| CA2775978A1 (en) | 2009-09-29 | 2011-04-07 | Protagen Ag | Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof |
-
2009
- 2009-08-13 TW TW098127225A patent/TW201008574A/zh unknown
- 2009-08-14 WO PCT/JP2009/003894 patent/WO2010021111A1/en not_active Ceased
- 2009-08-14 CN CN2009801413475A patent/CN102186977A/zh not_active Withdrawn
- 2009-08-14 SG SG2013062708A patent/SG193214A1/en unknown
- 2009-08-14 EP EP09808047A patent/EP2326718A4/en not_active Withdrawn
- 2009-08-14 KR KR1020117005944A patent/KR20110063456A/ko not_active Withdrawn
- 2009-08-14 AU AU2009283762A patent/AU2009283762A1/en not_active Abandoned
- 2009-08-14 JP JP2011507725A patent/JP2012500001A/ja not_active Ceased
- 2009-08-14 CA CA2734515A patent/CA2734515A1/en not_active Abandoned
- 2009-08-14 US US13/059,617 patent/US20110280898A1/en not_active Abandoned
- 2009-08-14 RU RU2011110504/10A patent/RU2011110504A/ru not_active Application Discontinuation
- 2009-08-14 MX MX2011001880A patent/MX2011001880A/es not_active Application Discontinuation
- 2009-08-17 US US12/542,638 patent/US8383590B2/en active Active
-
2011
- 2011-02-09 IL IL211131A patent/IL211131A0/en unknown
-
2012
- 2012-05-04 US US13/464,831 patent/US8623829B2/en active Active
-
2013
- 2013-01-17 US US13/744,354 patent/US8759481B2/en not_active Expired - Fee Related
- 2013-11-13 US US14/079,144 patent/US9067973B2/en active Active
-
2014
- 2014-05-09 US US14/274,373 patent/US9284349B2/en active Active
-
2016
- 2016-01-06 US US14/989,741 patent/US20160200764A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160200764A1 (en) | 2016-07-14 |
| EP2326718A1 (en) | 2011-06-01 |
| US8383590B2 (en) | 2013-02-26 |
| KR20110063456A (ko) | 2011-06-10 |
| WO2010021111A1 (en) | 2010-02-25 |
| SG193214A1 (en) | 2013-09-30 |
| TW201008574A (en) | 2010-03-01 |
| US20140141027A1 (en) | 2014-05-22 |
| AU2009283762A1 (en) | 2010-02-25 |
| JP2012500001A (ja) | 2012-01-05 |
| US20100040641A1 (en) | 2010-02-18 |
| US8623829B2 (en) | 2014-01-07 |
| US20130189291A1 (en) | 2013-07-25 |
| MX2011001880A (es) | 2011-03-29 |
| US9284349B2 (en) | 2016-03-15 |
| US8759481B2 (en) | 2014-06-24 |
| CN102186977A (zh) | 2011-09-14 |
| US20110280898A1 (en) | 2011-11-17 |
| US20140248300A1 (en) | 2014-09-04 |
| EP2326718A4 (en) | 2012-03-07 |
| US20120321649A1 (en) | 2012-12-20 |
| CA2734515A1 (en) | 2010-02-25 |
| US9067973B2 (en) | 2015-06-30 |
| IL211131A0 (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500001A5 (enExample) | ||
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2010506826A5 (enExample) | ||
| JP2008530975A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| RU2010154081A (ru) | Эпитопные пептиды iqgap3 вакцины, содержащие их | |
| JP2010523471A5 (enExample) | ||
| HRP20141233T1 (hr) | PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 | |
| CA2489227A1 (en) | Hla-a24-restricted cancer antigen peptides | |
| JP2012517799A5 (enExample) | ||
| JP2011524737A5 (enExample) | ||
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
| RU2011110376A (ru) | Эпитопные пептиды hig2 и urlc10 и содержание их вакцины | |
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| RU2010110545A (ru) | Cdh3-пептид и включающее его лекарственное средство | |
| JP2011529683A5 (enExample) | ||
| RU2009129531A (ru) | Вакцины на основе пептида foxp3 | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| JP2010514669A5 (enExample) | ||
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| JP2015529219A5 (enExample) | ||
| RU2011120447A (ru) | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины | |
| RU2018108197A (ru) | Пептид, полученный из depdc1, и содержащая его вакцина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140714 |